Financial news, mergers and acquisitions, partnerships, and alliances.
Shares jumped nearly 90 percent today after the firm said this morning that it has commercially launched its Target Selector NGS Lung Panel assay.
FLX Bio will apply Personalis' ImmunoID Next platform as part of a Phase I/II clinical trial evaluating its FLX475 drug in cancer therapy.
The firm has developed a digital platform that determines whether patients meet guidelines for genetic testing, and if so, what test they should receive.
The company also reported a decline in its net loss for the quarter on lower operating expenses due to a recent reorganization that included layoffs.
The test will guide clinical decision making related to Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus.
University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.
A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.
Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.
In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.